

	Name of the Issuer:	Suraksha Diagnostics Limited
--	---------------------	------------------------------

1	Type of Issue	Initial Public Offer
---	---------------	----------------------

2	Issue Size (Rs. Crores)	846.25
---	-------------------------	--------

3	Grade of issue along with name of the rating agency	
	Name	NA
	Grade	NA

4	Subscription Level (Number of times)	1.26 times*
---	--------------------------------------	-------------

Excluding Anchor allocations and after removing multiple and duplicate bids and technical rejection

Source : Post Issue Report

5	QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges	
	Particulars	%
	(i) On Allotment	32.32%
	(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2025)	35.83%
	(iii) at the end of 1st FY (March 31, 2025)	36.51%
	(iv) at the end of 2nd FY (March 31, 2026)	Not Available*
	(v) at the end of 3rd FY (March 31, 2027)	Not Available*

* QIB Holding not disclosed as reporting for the relevant period/fiscal year has not been completed

Source: Shareholding Pattern, as submitted to the Stock Exchange

6	Financials of the issuer	(Rs. Crores)		
	Parameters	1st FY (March 31, 2025)	2nd FY (March 31, 2026)	3rd FY (March 31, 2028)*
	Income from operations	252.09	310.41	Not Available
	Net Profit for the period	30.77	31.4	Not Available
	Paid-up equity share capital	10	10	Not Available
	Reserves excluding revaluation reserves	201.00	234	Not Available

*Financials not available as reporting for the relevant years has not been completed.

7	Trading status in the scrip of the issuer	
	Company's Equity Shares are listed on both BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")	
	The equity shares have not been been suspended or delisted.	
	Particulars	Status
	(i) at the end of 1st FY (March 31, 2025)	Frequently Traded
	(ii) at the end of 2nd FY (March 31, 2026)	Frequently Traded
	(iii) at the end of 3rd FY (March 31, 2027)	Not Available*

* Trading status not disclosed as the relevant fiscal year has not been completed.

8	Change, if any, in directors of issuer from the disclosures in the offer document		
	Particulars	Name of Director	Appointed / Resigned
	During year ended March 31, 2025	-	-
	During year ended March 31, 2026	Arun Sadhanandham	Resignation
	During year ended March 31, 2028	Not Available*	Not Available*

*Relevant fiscal years have not been completed.

Rs. In Crores

9	Status of implementation of project/ commencement of commercial production	
	Particulars	Remarks
	(i) as disclosed in the offer document	

	Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company and our Material Subsidiary namely, Electronics Bazaar FZC	Not Applicable
	General Corporate Purposes	Not Applicable
	(ii) Actual implementation	Not Applicable
	(iii) Reasons for delay in implementation, if any	Not Applicable

**Actual implementation of project/ commencement of project have not been completed.*

10	Status of utilization of issue proceeds	
	(i) as disclosed in the offer document	Not Applicable
	(ii) Actual utilization	
	(iii)Reasons for deviation, if any	

Actua lutilization of issue proceeds have not been completed.

11	Comments of monitoring agency, if applicable	
	(i) Comments on use of funds	Not Applicable
	(ii) Cooments on deviations, if any, in the use of proceeds of the issue from objects stated in the offer	
	(iii) Any other reservations expressed by the monitoring agency about the end use of funds	

12	Price-related data	
	Designated SE	BSE
	Issue Price (Rs.)	441.00
	Listing Date	06-Dec-24

Price parameters	At close of listing day	At close of 30th calendar day from listing day ⁽¹⁾	At close of 90th calendar day from listing day ⁽¹⁾	As at the end of March 31, 2025		
				Closing price during FY	High during FY	Low during FY
Market Price	417.95	377.85	277.40	257.8	449.00	233.15
Sensex	81510.05	79,223.10	75,901.40	77414.9	85978.3	70234.4
Sectoral Index	Not Comparable to any of the available sectorial indices					
Price parameters	As at the end of March 31, 2026 ⁽²⁾			As at the end of March 31, 2027 ⁽²⁾		
	Closing price during FY	High during FY	Low during FY	Closing price during FY	High during FY	Low during FY
Market Price	228.05	235.6	224.1	Not Available	Not Available	Not Available
Sensex	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Sectoral Index	Not Comparable to any of the available sectorial indices					

Source: Stock Exchange data. Where the 30th day / 90th day/ March 31 of a particular year falls on a holiday, the immediately following trading day has been considered

(1) The pricing data is not disclosed as the relevant period / fiscal years have not been completed

(2) In case of reporting dates falling on a trading holiday, values for the trading day immediately preceding the trading holiday have been

13	Basis for Issue Price				
	Accounting ratio	As disclosed in offer document*	At the end of 1st FY (March 31, 2025)**	At the end of 2nd FY (March 31, 2026)**	At the end of 3rd FY (March 31, 2028)**
EPS (Basic)	Issuer:				
	Consolidated	4.43	6.11	6.18	Not Available
	Peer Group				
	Dr. Lal Pathlabs	43.05	58.28	30.24	Not Available
	Metropolis Healthcare	24.95	27.99	9.19	Not Available
	Thyrocare	13.42	17.27	10.27	Not Available
	Vijaya Diagnostic	11.62	13.94	17.33	Not Available
	Industry Average	23.26	29.37	16.76	Not Available
P/E	Issuer:				
	Consolidated	33.05	42.19	36.90	Not Available
	Industry Average - Peer Group				
	Dr. Lal Pathlabs	77.08	48.23	43.39	Not Available
	Metropolis Healthcare	89.61	60.76	47.23	Not Available
	Thyrocare	65.52	58.33	34.04	Not Available
	Vijaya Diagnostic	86.50	66.36	49.71	Not Available
	Industry Average	79.65	58.42	43.59	
RoNW %	Issuer:				
	Consolidated	14.09%	15.92%	13.14%	Not Available
	Industry Average - Peer Group				
	Dr. Lal Pathlabs	20.35%	24.30%	20.12%	Not Available
	Metropolis Healthcare	12.26%	11.95%	12.55%	Not Available
	Thyrocare	13.34%	16.91%	27.84%	Not Available
	Vijaya Diagnostic	19.77%	19.80%	18.89%	Not Available
	Industry Average	16.43%	18.24%	19.85%	Not Available
NAV per share	Issuer:				
	Consolidated	33.66	40.56	47.01	Not Available
	Industry Average - Peer Group				
	Dr. Lal Pathlabs	221.53	259.92	149.65	Not Available
	Metropolis Healthcare	213.98	256.94	72.89	Not Available
	Thyrocare	99.48	103.17	36.78	Not Available

	<i>Vijaya Diagnostic</i>	64.21	77.53	91.69	Not Available
	<i>Industry Average</i>	149.80	174.39	87.75	Not Available

Notes

* Source: Prospectus for the offer dated December 3, 2024

**Not available as the relevant fiscal years have not been completed/ information not disclosed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

- (i) Basic earnings per Equity Share are computed in accordance with Indian Accounting Standard 33 ‘Earnings per Share’ for issuer company, notified by the Companies (Indian Accounting Standards) Rules, 2015,
- (ii) P/E - Closing Market Price as of relevant fiscal year end on BSE / Basic EPS for year ended
- (iii) RoNW - Return on net worth (%) is net profit after tax divided by net worth at the end of the year/period. Net Worth = Equity Share Capital + Reserves & Surplus excluding reval

- iv) Net asset value per equity share =Net worth as of the end of relevant year divided by the number of equity shares outstanding at the end of the year
- (v) EV / EBITDA Ratio is computed as the market capitalization of the listed industry peer on BSE, plus the total debt (non-current borrowings and current borrowings) of the respective company as on the end of the

Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com